Accès à distance ? S'identifier sur le proxy UCLouvain
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Primary tabs
- Open access
- 1.61 M
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès libre |
Publication date | 2022 |
Language | Anglais |
Journal information | "Journal of neurology, neurosurgery, and psychiatry" - Vol. 93, no. 12, p. 1330-1337 (2022) |
Peer reviewed | yes |
Publisher | BMJ Publishing Group ((United Kingdom) London) |
issn | 0022-3050 |
e-issn | 1468-330X |
Publication status | Publié |
Affiliations |
UCL
- SSS/IONS/CEMO - Pôle Cellulaire et moléculaire UCL - (SLuc) Service de neurologie |
MESH Subject | Humans ; Fingolimod Hydrochloride ; Natalizumab ; Cladribine ; Multiple Sclerosis ; Cohort Studies ; Immunosuppressive Agents ; Treatment Outcome ; Multiple Sclerosis, Relapsing-Remitting ; Recurrence ; Withholding Treatment |
Keywords | MULTIPLE SCLEROSIS ; NEUROIMMUNOLOGY |
Links |
Bibliographic reference | Zhu, Chao ; Zhou, Zhen ; Roos, Izanne ; Merlo, Daniel ; Kalincik, Tomas ; et. al. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.. In: Journal of neurology, neurosurgery, and psychiatry, Vol. 93, no. 12, p. 1330-1337 (2022) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/276377 |